| Literature DB >> 8082316 |
B R Osswald1, F E Klee, S Wysocki.
Abstract
CA 19-9 is used as a tumour marker of the upper gastrointestinal tract. However, extremely elevated CA 19-9 levels are found also in patients with benign diseases. Cholestasis was present in 97.1% of patients with high elevated CA 19-9, independent of their primary disease. 50% of patients with non-malignant diseases and increased CA 19-9 levels showed liver cirrhosis, cholecystitis, pancreatitis and/or hepatitis. In 8.8% no explanation was found for the extremely high CA 19-9 level. The results provide evidence of different factors influencing the CA 19-9 level.Entities:
Mesh:
Substances:
Year: 1993 PMID: 8082316 DOI: 10.1155/1993/234238
Source DB: PubMed Journal: Dis Markers ISSN: 0278-0240 Impact factor: 3.434